Developability assessment is a critical part of the evaluation and selection of candidates for further optimization and development for biologics researchers.
This work entails collecting, ranking, and prioritizing a huge list of quality attributes of many candidates; however, in the early development stage, it is critical to minimize the amount of time and material used to create developability profiles in order to save time, materials, and cost.
Prometheus Panta offers a 4-in-1 technology platform for collecting stability characteristics critical for early development workflows.
In this webinar, learn more about how the technologies work, how they are applied to different aspects of developability profiling, and how the discovery group at Merck used Panta to assess multiple developability characteristics of their mAb therapeutics and gained deeper insight into the quality attributes of their candidates.
Watch this video to learn:
- Which technologies are in the Prometheus Panta instrument, and what they tell you about your protein-based therapeutics
- How the Protein Science team from Merck & Co. used Prometheus Panta to rank and characterize engineered antibodies
- Why high-resolution, trustworthy data is so critical to a successful developability work
Interested in Prometheus Panta? Contact Specialist
